



**One-Incubation One-Hour Multiplex ELISA Enabled by  
Aqueous Two-Phase Systems**

Journal:	<i>Analyst</i>
Manuscript ID	AN-ART-02-2020-000383.R1
Article Type:	Paper
Date Submitted by the Author:	26-Mar-2020
Complete List of Authors:	<p>Tongdee, Mintra; Mahidol University Faculty of Science, Department of Chemistry and Center of Excellence for Innovation in Chemistry; Georgia Institute of Technology, Department of Biomedical Engineering  Yamanishi, Cameron; Georgia Institute of Technology, Department of Biomedical Engineering  Maeda, Midori; Georgia Institute of Technology, Department of Biomedical Engineering  Kojima, Taisuke; Georgia Institute of Technology, Department of Biomedical Engineering  Dishinger, John; University of Michigan, PHASIQ, Inc.  Chantiwas, Rattikan; Mahidol University Faculty of Science, Department of Chemistry and Center of Excellence for Innovation in Chemistry  Takayama, Shuichi; Georgia Institute of Technology, Department of Biomedical Engineering</p>

1  
2  
3 **One-Incubation One-Hour Multiplex ELISA Enabled by**  
4  
5  
6 **Aqueous Two-Phase Systems**  
7  
8  
9

10  
11  
12  
13  
14 Mintra Tongdee, <sup>a,b</sup> Cameron Yamanishi, <sup>b</sup> Midori Maeda, <sup>b</sup> Taisuke Kojima, <sup>b</sup> John Dishinger, <sup>c</sup>  
15  
16 Rattikan Chantiwas<sup>a</sup> and Shuichi Takayama<sup>b\*</sup>  
17  
18  
19

20  
21  
22  
23 <sup>a</sup>Department of Chemistry and Center of Excellence for Innovation in Chemistry and Flow  
24  
25 Innovation-Research for Science and Technology Laboratories (FIRST Labs),  
26  
27 Faculty of Science, Mahidol University, Rama VI Rd., Bangkok 10400, Thailand  
28  
29

30 <sup>b</sup>Department of Biomedical Engineering, Georgia Institute of Technology,  
31  
32 Atlanta 30332, Georgia, USA  
33

34  
35 <sup>c</sup> PHASIQ, Inc., Ann Arbor, Michigan 48109, USA  
36  
37  
38  
39  
40

41 \* Corresponding author: [takayama@gatech.edu](mailto:takayama@gatech.edu)  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **1 Abstract**  
4  
5  
6  
7

8 2  
9 3 This work describes a convenient one-hour enzyme-linked immunosorbent assay (ELISA)  
10 4 formulated with conventional antibodies and horse radish peroxidase (HRP) reagents. The  
11 5 method utilizes aqueous two-phase system (ATPS) droplet formation based on poly(ethylene  
12 6 glycol) (PEG)-containing sample solution-triggered rehydration of dehydrated dextran (DEX)  
13 7 spots that contain all antibody reagents. Key advances in this paper include development of a  
14 8 formulation that allows a quick 1-hour overall incubation time and a procedure where inclusion  
15 9 of the HRP reagent in the PEG solution reduces the number of washing and incubation steps  
16 10 required to perform this assay. As an assay application, a 5-plex cytokine test compares cytokine  
17 11 secretion of differentially-treated human ThP-1 macrophages. Given the use of only readily  
18 12 available reagents and a common western blot imaging system for the readout, this method is  
19 13 envisioned to be broadly applicable to a variety of multiplex immunoassays. To facilitate broader  
20 14 use, companion image processing software as an ImageJ plugin is also described and provided.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

23    *Keywords:* One-incubation ELISA; Aqueous two-phase systems; Cytokines; Multiplex detection

## 1. Introduction

Enzyme-linked immunosorbent assays (ELISAs) enable selective quantification of a variety of analytes, including small molecules, proteins, viruses, and bacteria, by employing an enzyme linked antigen or antibody as a marker for the detection of specific analytes.<sup>1</sup> When appropriate antibodies are available, ELISA can provide high sensitivity and high specificity.<sup>2</sup> However, this technique can involve time-consuming procedures and tedious washing processes. Moreover, it is normally limited to only one target at a time.<sup>3, 4</sup> Contemporary studies have shown that many diseases and biological processes involve multiple different proteins, highlighting the need for measurement of multiple targets within the same sample.<sup>5-7</sup>

Recent advances have enabled multiplex ELISA, allowing for simultaneous detection of multiple targets, conserving time and reagents, thus enabling analysis of more complex biological processes.<sup>8-13</sup> However, the typical multiplex sandwich ELISA assay involves three separate incubation steps for three different protein-ligand interactions, as listed in Fig. 1(A): (i) binding of analyte to capture antibody (cAb), (ii) binding of detection antibody (dAb) to cAb-bound analyte, and (iii) binding of streptavidin-HRP to the analyte-bound dAb through a biotin-streptavidin interaction.<sup>14-17</sup> Note that each incubation step is also followed by washing procedures.<sup>18, 19</sup> While cAbs for different targets can be spatially segregated from each other by arraying different cAbs in different positions within single microwells, the dAbs are typically added as a solution mixture to the entire array within the microwells making multiplex ELISA susceptible to unintended cross reactions between antibody reagents.<sup>20</sup> To eliminate this problem of dAb cross-reactions, we previously developed aqueous two-phase system (ATPS)-based

1  
2  
3 47 approaches where dAbs in solution remain spatially confined to phase-separated microdroplets  
4  
5 48 during the dAb binding step. ATPSs form when certain polymers (e.g. PEG and DEX) are mixed  
6  
7 49 in aqueous solutions above a critical concentration.<sup>21</sup> When appropriately formulated, the  
8  
9  
10 50 resulting two immiscible aqueous solutions can partition proteins, such as antibodies, selectively  
11  
12 51 to one of the two aqueous phases enabling compartmentalization of dAbs to microdroplets.  
13  
14  
15 52

16  
17 53 Table 1 compares the reported multiplex ATPS ELISA of this paper against previously-  
18  
19 54 published multiplex ATPS ELISA based on assay time, number of incubations, number of  
20  
21 55 washes, materials utilized, type of microwell plate used, concentration range detected, signal to  
22  
23 56 noise ratio (S/N) and limit of detection (LOD). Our first publications on this topic demonstrated  
24  
25 57 that ATPSs can be used to eliminate dAb cross-reactions in both heterogeneous and homogenous  
26  
27 58 immunoassays such as AlphaLISA<sup>TM</sup>.<sup>22, 23</sup> More recently, our group showed that the ATPS  
28  
29 59 ELISA technique could be made in a format with the cAbs, dAbs, and dextran (DEX) pre-  
30  
31 60 arrayed and dehydrated for easy storage.<sup>24</sup> In this format depicted in Fig. 1(B), dAbs in DEX  
32  
33 61 solution are microarrayed over corresponding cAb-coated microbasins followed by dehydration  
34  
35 62 to allow ready-to-use plates to be stably stored. When ready to use in assays, sample aliquots are  
36  
37 63 diluted 1:1 with a poly (ethylene glycol) (PEG) diluent then added into microwells with the pre-  
38  
39 64 spotted and dehydrated antibodies (cAbs and dAbs) and DEX. Aqueous fluid from the PEG  
40  
41 65 solution rehydrates the DEX and antibodies to form immiscible DEX microdroplets within the  
42  
43 66 PEG milieu of the microwells. The phase separation and partitioning confine antibodies within  
44  
45 67 the DEX microdroplets while target proteins move from the PEG phase into the DEX phase  
46  
47 68 microdroplets for antibody binding. In this previously published assay, the cAb-analyte binding  
48  
49 69 and analyte-dAb binding steps (Fig. 1(B), steps i, ii) are integrated into one and required 4 hours  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 70 of incubation. Subsequent washing, 20 minutes incubation with streptavidin-HRP, washing, and  
4  
5 71 addition of HRP substrate generate the readout signals.  
6  
7  
8 72

9  
10 73 In this work, we report an additional evolution of the ATPS ELISA to shorten assay time and  
11  
12 74 enhance convenience while maintaining high sensitivity and robustness. One modification is the  
13  
14 75 inclusion of HRP reagent in the sample PEG solution from the beginning so that there is only  
15  
16 76 one incubation step that requires washing procedures before signal readout. We also altered the  
17  
18 77 PEG-DEX formulation to allow all three-binding interactions (i, ii, iii, namely cAb-analyte  
19  
20 78 binding, analyte-dAb binding, and dAb-HRP binding) to take place in a single, 1-hour  
21  
22 79 incubation, as shown in Fig. 1(C). This procedure reduces total time for the ELISA by 5-fold,  
23  
24 80 while also minimizing wash steps. In addition to user convenience, this new assay maintains  
25  
26 81 previously-reported advantages of ATPS ELISA, such as two orders of magnitude lower  
27  
28 82 consumption of dAb and minimizing dAb cross-reactions due to ATPS partitioning and  
29  
30 83 confinement. Another improvement over our previous report<sup>24</sup> is the use of a black rather than  
31  
32 84 clear plastic microwell plate to reduce optical cross-talk between microbasins and microwells.  
33  
34 85 Lastly, we analyze secreted cytokines from two populations of THP-1 macrophage subjected to  
35  
36 86 different stimulation conditions using this convenient one-incubation ELISA and reveal  
37  
38 87 signatures from macrophages at late time points after M1 and M2 polarization and refreshment  
39  
40 88 of media. This rapid, one-incubation ATPS ELISA is a significant enhancement over the  
41  
42 89 previously published ATPS ELISA methods and is envisioned to broaden the range of potential  
43  
44 90 applications.<sup>25, 26</sup>  
45  
46  
47  
48  
49  
50  
51  
52  
53

## 54 92 **2. Experimental**

55  
56  
57  
58  
59  
60

93

## 94 **2.1. Chemicals and reagents**

95 ELISA DuoSet kits for human IL-6 (DY206), human IL-10 (DY217B-05), human TNF- $\alpha$   
96 (DY210), human IL-1 $\beta$  (DY201) and human CCL18 (DY394-05) were acquired from R&D  
97 Systems. Each DuoSet kit contains cAbs, dAbs, antigen standards and 40 $\times$  streptavidin-HRP.  
98 SuperSignal<sup>TM</sup> ELISA Femto Substrate (Product no. 37075) was purchased from Thermo Fisher  
99 Scientific (Rockford, IL, USA). All cAbs were diluted in 1 $\times$ PBS pH 7.4 (10010-023) from  
100 Gibco, Life Technologies. Other reagents were prepared in buffers containing indicated amounts  
101 of distilled water (Gibco, Life Technologies, 15230-170), 5 $\times$ StabilCoat (SurModics, Eden  
102 Prairie, MN, USA), Tween 20, dextran (9004-54-0) MW 500,000 g mol<sup>-1</sup>, polyethylene glycol  
103 (25322-68-3) MW 35,000 g mol<sup>-1</sup> (Sigma, St. Louis, MO, USA), and bovine serum albumin  
104 (protease free and fatty acid poor, 82-067-3) (Millipore, Burlington, MA, USA).

105

## 106 **2.2 Imaging fluorescence of FITC-dAb in DEX droplets**

107 A fluorescent stereo microscope (Leica M165 FC, Leica Microsystems) was used for all bright  
108 field and fluorescence imaging ( $\lambda_{\text{ex}}$ : 490 nm,  $\lambda_{\text{em}}$ : 520 nm). Investigation of conditions for one-  
109 incubation assay: selection of APTS system (*i.e.* APTS condition) and blocking buffer were  
110 carried out by using custom-fabricated 96-well injection molded black microwell plates with 1.7  
111 mm diameter microbasins (9 per well) (PHASIQ, Ann Arbor, Michigan), see image of the plate  
112 in Electronic Supplementary Information (ESI 1), Fig. S2. Details conditions are given below.

113

114 ***Selection of APTS formulation:*** FITC-dAb retention in DEX droplets submerged in PEG

115 solutions was analyzed for various concentration combinations of PEG and DEX in Fig. 2(A and



1  
2  
3 116 B). Firstly, we visualized antibody partitioning and confinement in DEX microdroplets. To  
4  
5 117 analyze this, 3×StabilCoat solutions were spotted into the middle microbasin, out of an array of 9  
6  
7  
8 118 microbasins, in each microwell (1μL/1 microbasin), by an electronic pipette (Repeater®,  
9  
10 119 Eppendorf, Hauppauge, NY, USA) to prevent adsorption of the FITC-dAb to be added to this  
11  
12 120 microbasin later. The remaining 8 microbasins were then filled with DEX solutions (1μL/1  
13  
14  
15 121 microbasin) by use of the Repeater pipetter. The plates were then dried in a desiccator for 1 hour.  
16  
17 122 FITC-dAb-containing DEX solutions (1μL/1 microbasin) were then spotted into the one middle  
18  
19  
20 123 microbasin that contains the dried 3×StabilCoat spots. After a 1 hour drying step, PEG solutions  
21  
22 124 were added into each microwell (100 μL/1 microwell). The plate was imaged by fluorescence  
23  
24  
25 125 microscopy at designated timepoints. Concentrations (%w/w) of the PEG and DEX solutions that  
26  
27 126 were spotted into microbasins or added to microwells were as follows for experiments  
28  
29 127 represented by Fig. 2(A-D): (a) 9%-9%, (b) 5%-9%, (c) 9%-5%, (d) 5%-5%, (e) 5%-3%, (f) 3%-  
30  
31 128 5% and (g) 3%-3% (see more detail in ESI 1, Fig. S1). We note that under these experimental  
32  
33  
34 129 conditions where DEX solutions are dried out and PEG solutions then added for rehydration, the  
35  
36 130 overall concentration of PEG and DEX during the assay becomes: (a) 9%PEG-0.81%DEX, (b)  
37  
38 131 5%PEG-0.81%DEX, (c) 9%PEG-0.45%DEX, (d) 5%PEG-0.45%DEX, (e) 5%PEG-0.27%DEX,  
39  
40  
41 132 (f) 3%PEG-0.45%DEX and (g) 3%PEG-0.27%DEX. These latter concentrations are what is  
42  
43 133 relevant for consideration in phase diagrams. Fig. 2(C) shows positions of PEG and DEX  
44  
45 134 concentration after rehydration during the assays and relate it to the binodal curve. PEG-DEX  
46  
47  
48 135 ATPS binodal curve were determined by the diluting method. As stock solutions, we used 20  
49  
50 136 %w/w DEX and 20 %w/w PEG in PBS. Various phase-separating solutions were diluted by PBS  
51  
52 137 solution down to binodal points determined as the point where the phase boundary disappears  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 138 after a 6000 rpm × 5 min centrifugation. Measurements were conducted at 25 °C. Data were fit  
4  
5 139 using a previously reported method<sup>27</sup> using the R program (<https://www.r-project.org/>).  
6  
7

8 140  
9  
10 141 **Comparison of blocking buffers:** Five types of blocking buffers (3× StabilCoat™, 1×  
11  
12 142 StabilCoat™, 5% BSA, 5% goat serum, and 0.1% Chonblock™ with 0.05% goat serum) were  
13  
14 143 spotted into 1 microbasin of each microwell (1µL/1 microbasin). The plate was dried in a  
15  
16 144 desiccator for 1 hour. Then, 1 µL of 5% DEX containing IgG FITC-antibodies was spotted onto  
17  
18 145 the dry blocking buffer spots. After 1 hour of additional drying, the plate was imaged by  
19  
20 146 brightfield and fluorescence microscope as shown in Table 3. Table 3 also includes impact of  
21  
22 147 blocking buffers on assay performance.  
23  
24  
25

26 148  
27  
28

### 29 149 **2.3 Singleplex detection by standard ELISA procedure**

30  
31 150 Singleplex ELISA was performed according to manufacturer instructions from R&D DuoSet  
32  
33 151 ELISA at room temperature (25 °C). Briefly, microwell plates were prepared as follows: 100 µL  
34  
35 152 of the working dilution of cAbs were added to each microwell of a 96-well microplate (DY990  
36  
37 153 from R&D System) and incubated overnight. The plates were washed sequentially 3 times with  
38  
39 154 400 µL of 0.05% Tween 20 in PBS each, then blocked with 300 µL of 1% BSA in PBS (1×, pH  
40  
41 155 7.4) for 1 hour. After blocking, the plate was washed sequentially 3 times. Next, antigen standards  
42  
43 156 or sample (prepared in 1%BSA in PBS in a two-fold dilution series) were added at 100 µL per  
44  
45 157 microwell and the plate was incubated for 2 hours at room temperature in the dark. The plate was  
46  
47 158 washed and incubated with 100 µL of appropriate dAb per microwell for a 2-hour incubation.  
48  
49 159 Following additional 3 times washing, 100 µL of streptavidin-HRP was added to each microwell  
50  
51 160 at the manufacturer's recommended concentration and the plate was incubated for 20 minutes in  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 161 the dark. After a final wash, 100  $\mu\text{L}$  of enzyme substrate peroxidase chromogen was added into  
4  
5 162 each microwell. After 20 minutes of incubation in the dark, 50  $\mu\text{L}$  of 0.18 M  $\text{H}_2\text{SO}_4$  was added  
6  
7 163 into each microwell to stop the reaction. Lastly, a BioTek Synergy H4 microplate reader was used  
8  
9 164 to measure absorbance at 450 nm.  
10  
11  
12  
13

## 14 166 **2.4 Multiplex detection by ATPS ELISA**

15  
16  
17 167 Two methods of ATPS ELISA (*i.e.* one-and two- incubations) were performed using custom 96-  
18  
19 168 well injection-molded black plates (PHASIQ, Inc). Microplates were first washed prior to antibody  
20  
21 169 immobilization steps by spraying with ethanol and rinsing with distilled water, the washed plated  
22  
23 170 were kept in a desiccator for drying and storing until needed.  
24  
25

26 171

### 27 28 172 **2.4.1 One-incubation ATPS ELISA procedure**

29  
30  
31 173 Firstly, capture antibodies (cAb) were arrayed at indicated concentrations by repeater pipetter  
32  
33 174 pipetting of 1.0  $\mu\text{L}$  of cAb solution into appropriate microbasins within each microplate microwell.  
34  
35 175 The cAb solution-arrayed plates were covered and stored in the dark at room temperature for 90  
36  
37 176 minutes. After that the plates were washed three times with wash buffer (*i.e.* 0.05% Tween 20 in  
38  
39 177 PBS) using a plate washer (BioTek™ 50TS microplate washer with 300  $\mu\text{L}$  of wash buffer per  
40  
41 178 microwell, 3 cycles and 3 seconds for shaking in each cycle) to remove all unbound cAbs. Then,  
42  
43 179 100  $\mu\text{L}$  of 5% sucrose in PBS was added into each microwell to stabilize the cAbs against  
44  
45 180 denaturation during dehydration. After removing the sucrose solution, plates were dried in a  
46  
47 181 desiccator for 40 minutes. Next, indicated blocking buffers were arrayed into every microbasin  
48  
49 182 containing cAb using a repeater pipette, followed by an additional 40-minute drying step.  
50  
51 183 Detection antibody was prepared in distilled water with DEX at various concentrations (*i.e.* 9%,  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 184 5% and 3%w/w. These DEX-containing dAb solutions were spotted at 1  $\mu\text{L}$  per microbasin and  
4  
5 185 dried in a vacuum desiccator overnight. Next, antigen standards or samples containing 0.05%  
6  
7  
8 186 Tween 20, 0.5% BSA, and indicated concentrations of streptavidin-HRP in PBS were diluted 1:1  
9  
10 187 with a solution containing indicated concentrations of PEG, 0.05% Tween 20, 0.5% BSA, and  
11  
12 188 indicated concentrations of streptavidin-HRP in PBS. A 7-point standard curve was constructed  
13  
14  
15 189 using 2-fold dilutions starting from a 2,000  $\text{pg mL}^{-1}$  solution. After adding 100  $\mu\text{L}$  of the different  
16  
17 190 dilution standard solutions into microwells, plates were incubated for 1 hour. The plates were  
18  
19 191 washed 6 times with wash buffer using a plate washer to remove all unbounded proteins and  
20  
21 192 viscous DEX components. Finally, 100  $\mu\text{L}$  of the chemiluminescence substrate was added into  
22  
23 193 each microwell before taking images using a BioRad ChemiDoc MP+ Western Blot reader with  
24  
25  
26 194 an exposure time of 40 seconds.  
27

195

#### 196 **2.4.2 Two-incubation ATPS ELISA procedure**

197 The two-incubation ELISA is different from the one-incubation ELISA in the following ways. For  
198 the two-incubation ELISA, there is no streptavidin-HRP in the PEG solution. Thus, after the  
199 sample incubation step, there is an addition incubation step with 100  $\mu\text{L}$  of streptavidin-HRP  
200 solution. This also necessitates an additional wash procedure (microwells were washed 6 times)  
201 between the sample incubation and streptavidin-HRP solution incubation step. The details of this  
202 two-incubation procedure can be found in a previous report from our group.<sup>28</sup>

203

#### 204 **2.4 Cell culture and macrophage preparation**

205 Human monocytic THP-1 cells (ATCC, TIB-202) were grown in Roswell Park Memorial Institute  
206 (RPMI) 1640 biotin-free medium (MyBioSource, MBS653376) with 10% fetal bovine serum

1  
2  
3 207 (FBS) (Gemini Bio-products), and 1% penicillin-streptomycin (Gibco). Cells were seeded in T75  
4  
5 208 flasks at a density of  $1 \times 10^6$  cells  $\text{mL}^{-1}$ , and differentiated into macrophages as described by Spiller  
6  
7  
8 209 et. al.<sup>29</sup>, with 320 nM phorbyl 12-myristate 13-acetate (PMA, Sigma) and incubated overnight.  
9  
10 210 The activated and adherent THP-1 derived macrophages were washed three times with fresh media  
11  
12 211 to remove PMA. THP-1-derived macrophages were then detached using Accutase (Sigma, A6964)  
13  
14  
15 212 for 5-10 minutes at 37°C followed by gentle scraping before being collected and counted using a  
16  
17 213 Nexcelom Cell Counter. Subsequently, macrophages were seeded into T25 flasks for differential  
18  
19 214 polarization. One sub-population of macrophages were treated with 100 ng  $\text{mL}^{-1}$   
20  
21 215 lipopolysaccharides (LPS, Sigma, L2630), and 100 ng  $\text{mL}^{-1}$  IFN- $\gamma$  (R&D Systems, 285-IF), and  
22  
23  
24 216 incubated for 48 h. Another sub-population was treated by adding 20 ng  $\text{mL}^{-1}$  IL-13 (R&D  
25  
26 217 Systems, 213-ILB), and 40 ng  $\text{mL}^{-1}$  IL-4 (R&D Systems, 204-IL), and incubated for 48 h. Cells  
27  
28 218 were washed three times in cell culture medium and incubated for 24 hours to allow the  
29  
30  
31 219 macrophages to secrete cytokines into the fresh medium. Supernatants were collected and  
32  
33 220 centrifuged at  $200 \times g$  for 5 minutes to remove dead cells and debris, then frozen at  $-80^\circ\text{C}$  for  
34  
35 221 subsequent ELISA analysis.  
36  
37  
38 222

## 40 223 **2.5 Fluorescence/chemiluminescence imaging: Fiji image J**

41  
42 224 Fiji image J Software (<http://imagej.nih.gov/ij/>) was used for evaluation of fluorescence intensity  
43  
44 225 from FITC-dAb images and all chemiluminescence images from ELISA. A custom Fiji image J  
45  
46  
47 226 plugin was written to aid in identifying and outlining microbasin areas within each microwell  
48  
49 227 (software details of custom Fiji image J plugin is in ESI 3). Briefly, the plugin guides the user  
50  
51 228 through image rotation and determination of the size and locations of microbasins to generate a  
52  
53  
54  
55  
56  
57  
58  
59  
60

229 plate-wide map. The plugin then measured the average chemiluminescence intensity for each  
230 microbasin, exporting an Excel sheet with annotated microwells and microbasin intensities.

231

## 232 **2.5 Evaluation of analytical characteristic of ELISA assay**

233 Standard curves were constructed and fitted with a four-parameter logistic function in Graph Pad  
234 Prism. The limit of detection (LOD) was calculated as  $LOB + 1.65$  (SD of low concentration  
235 sample), where LOB is the limit of blank and SD is the standard deviation. LOB is the highest  
236 concentration of apparent analyte expected to be found where replications of a blank sample  
237 containing no analyte are investigated. LOB was computed from  $LOB = \text{mean of blank} + 1.645(\text{SD}$   
238 of blank). Signal to noise ratios (S/N) were calculated as mean signal from the highest antigen  
239 standards ( $2,000 \text{ pg mL}^{-1}$ ) divided by mean of the blank, assuming that noise does not correlate  
240 with signal intensity. Coefficient of variation (CV) was calculated as percent of SD from antigen  
241 standard signal divided by mean of the signal. A *t-test* was performed by GraphPad InStat software  
242 (GraphPad Software Inc., San Diego, CA, USA) for statistical analysis (unpaired *t-test*) between  
243 different macrophage stimulation conditions (Section 3.3).

244

## 245 **3. Results and discussion**

246

247 In this work, we compare three ELISA formats, as shown in Fig. 1(A-C). A standard ELISA in  
248 Fig. 1(A) has three incubation steps; one for antigen capture by surface immobilized cAb, one for  
249 dAb binding, and another for HRP binding to the dAb. Each incubation step is also accompanied  
250 by washing steps resulting in a total assay time of 4 hours with three separate incubation steps and  
251 accompanying washing steps. For the two-incubation ATPS ELISA that we reported previously,

1  
2  
3 252 Fig. 1(B), dAbs are pre-spotted reducing the number of incubations and accompanying washing  
4  
5 253 steps to two. Our newly described one-incubation ELISA includes HRP in the sample PEG  
6  
7 254 solution and has an optimized PEG and DEX formulation, as described below, that not only  
8  
9 255 reduces the number of incubation and washing steps but also reduces incubation time by 4-fold as  
10  
11  
12 256 well (1 hour), Fig. 1(C).  
13  
14  
15 257

### 17 258 **3.1 Optimization of one-incubation ATPS ELISA**

19 259 In consideration of recent work by our group, showing that ATPS composition can influence mass  
20  
21 260 transport within the rehydrating DEX phase<sup>28</sup>, we examined ATPS composition to balance the  
22  
23 261 competing factors of high polymer content for high dAb retention in the DEX phase, and low  
24  
25 262 polymer content for low viscosity and improved mass transport.  
26  
27  
28 263

#### 31 264 **3.1.1 Investigation of ATPS condition**

33 265 The molecular weights and concentrations of PEG and DEX are key parameters for ATPSs.  
34  
35 266 Based on prior experience with different molecular weight polymers<sup>22, 30</sup>, here, we focus on PEG  
36  
37 267 35,000 and DEX T500 and tested varying concentrations of the polymers. Use of higher polymer  
38  
39 268 concentrations leads to generation of ATPSs with more distinct compositions and longer tie-lines  
40  
41 269 often increasing partitioning of dAbs and antigen into the DEX phase. Higher polymer  
42  
43 270 concentrations, however, also increase viscosity and reduce transport including rehydration- and  
44  
45 271 diffusion-driven convection.<sup>28</sup> For this one-incubation assay that includes HRP in the PEG phase,  
46  
47 272 higher PEG concentrations also increased the amount of non-specific background signal  
48  
49 273 generated. As shown in Fig. 2(A-D), we tested seven different formulations of PEG-DEX where  
50  
51 274 the final concentrations are (%w/w were; (a) 9%PEG-0.81%DEX, (b) 5%PEG-0.81%DEX, (c)  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 275 9%PEG-0.45%DEX, (d) 5%PEG-0.45%DEX, (e) 5%PEG-0.27%DEX, (f) 3%PEG-0.45%DEX  
4  
5  
6 276 and (g) 3%PEG-0.27%DEX). Fig. 2(A and B) shows how the 7 different formulations affect  
7  
8 277 FITC-dAb retention in DEX droplet and S/N from analysis of IL-6 (see more detail in ESI 1, Fig.  
9  
10 278 S1). Fig. 2C shows the locations of the ATPS compositions (a-g) relative to the binodal curve.  
11  
12 279 PEG-DEX concentrations at or above the binodal curve phase separate whereas concentrations  
13  
14 280 below the binodal curve results in just one phase. A majority of the goat anti-human IgG FITC-  
15  
16 281 antibodies are retained within DEX phases over the course of 1 hour for high and medium  
17  
18 282 concentration of PEG (points above binodal curve, a-e) but not at the lower concentration of  
19  
20 283 PEG (points below binodal curve, g-f). Moreover, size and shape of DEX droplets remain  
21  
22 284 consistent over this period. We next determined the calibration curves for a singleplex IL-6  
23  
24 285 ATPS ELISA using the same 7 different PEG-DEX formulations (a-g), Fig. 2(D). Each ATPS  
25  
26 286 condition (a-g) was also performed with one-incubation ELISA and the calculated LODs were  
27  
28 287 230, 25, 30, 1.8, 12, 95 and 270 pg mL<sup>-1</sup>, respectively, as shown in Fig. 2(D). Low PEG and  
29  
30 288 DEX concentrations, as in points f and g in Fig. 2(C) have low antibody retention in DEX as  
31  
32 289 shown in Fig. 2(A and B) leading to low signal and low sensitivity as expected because these  
33  
34 290 PEG-DEX concentrations are below the binodal curve after rehydration with PEG solution.  
35  
36 291 While phase separation is observed initially due to sufficiently high local DEX concentration,  
37  
38 292 this goes away over time eliminating the ability to localize antibodies. The high PEG and DEX  
39  
40 293 concentrations, point a, b and c in Fig. 2(C), produced high background. Surprisingly, high PEG  
41  
42 294 and DEX concentrations (point a and c) that yield high antibody retention in DEX droplets also  
43  
44 295 had lower signal than the moderate concentrations. This may be due to the high viscosity, which  
45  
46 296 reduces convective and diffusive transport. The medium PEG and DEX concentration, point d in  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 297 Fig. 2(C), balanced the two competing needs of a high signal and low noise, providing the best  
4  
5 298 standard curve.  
6  
7

8 299

### 10 300 **3.1.2 Incubation time**

11  
12 301 The typical sandwich ELISA assay involves three separate incubation steps for three different  
13  
14 302 protein-ligand interactions: (i) binding of analyte to cAb, (ii) binding of dAb to cAb-bound  
15  
16 303 analyte, and (iii) binding of HRP to the analyte-bound dAb through a biotin-streptavidin  
17  
18 304 interaction. Each incubation step is also followed by wash steps. In our previously published  
19  
20 305 multiplex ATPS ELISA assay<sup>24</sup>, we integrated the first two binding incubations into one step  
21  
22 306 which took 4 hours, followed by wash, incubation with HRP for another 20 minutes, another  
23  
24 307 wash, and then reading chemiluminescent signal. In a more recent singleplex ATPS ELISA that  
25  
26 308 also integrates the first two binding incubations<sup>28</sup>, we demonstrated a formulation with enhanced  
27  
28 309 internal convection that provided signals with just a 15-minute incubation time rather than 4  
29  
30 310 hours, although with slightly inferior sensitivity. For our new one-incubation ELISA, we  
31  
32 311 investigated incubation times of 15 minutes, 1 hour and 4 hours as shown in Table 2.  
33  
34  
35  
36  
37

38 312

39  
40 313 We found that in our new procedure that integrates all three-binding interaction into one  
41  
42 314 incubation with 1 hour provided an optimal time for incubation, it provided sufficiently high  
43  
44 315 signal with low background signal that leads to high S/N and low LOD (see details in ESI 1, Fig.  
45  
46 316 S3 and S4). The shorter time (15 minutes) was not sufficient time for strong signals to be  
47  
48 317 obtained. On the other hand, a 4-hour incubation also did not enhance sensitivity because of a  
49  
50 318 higher background signal.  
51  
52

53  
54 319  
55  
56  
57  
58  
59  
60

### 320 3.1.3 Blocking buffer

321 Blocking buffer solutions composed of proteins, surfactants, or other additive compounds  
322 minimize aggregation, precipitation, and nonspecific interaction of reagents and analyte to  
323 surfaces. Blocking buffers can also stabilize antibody molecules on dried surfaces through a  
324 variety of mechanisms, including hydrogen bonding replacement and vitrification.<sup>31</sup>  
325 Identification of an appropriate blocking scheme is critical for achieving high signal-to-noise  
326 ratios. Table 3 lists five types of blocking buffers we tested.

327  
328 We determined the calibration curves for an ATPS ELISA using the 5 different blocking buffers:  
329 3× StabilCoat™, 1× StabilCoat™, 5% BSA, 5% goat serum, and 0.1% Chonblock™ with 0.05%  
330 goat serum (see details in ESI 1, Fig. S5).<sup>32, 33</sup>

331  
332 Bovine Serum Albumin (BSA) is a commonly used blocking agents typically used at a 1 to 5%  
333 concentration. As displayed in Table 3, dehydrated 5%BSA-5%DEX generates an inconsistent,  
334 porous surface during dehydration that led to low repeatability and low sensitivity. Use of goat  
335 serum and Chonblock™ led to weak signals. Chonblock™ had high background signal that led  
336 to low sensitivity. StabilCoat™ produced dehydrated DEX spots with the smoothest surface  
337 (Table 3) and provided high repeatability in IL-6 ELISA. The use of 3× StabilCoat™ provided  
338 better sensitivity than 1× StabilCoat™. The concentrated buffer of 3× StabilCoat™ was more  
339 efficient at blocking nonspecific binding species than the recommended 1× StabilCoat™, as  
340 shown by the lower background signal.

341

### 342 3.1.4 Capture antibody, detection antibody and HRP concentrations

1  
2  
3 343 Selection of suitable concentrations of capture antibody, detection antibody and HRP for one-  
4  
5 344 incubation ATPS ELISA was performed (see Fig. 1(C), Sections 2.4.1 for experiments).  
6  
7  
8 345

9  
10 346 **Capture antibody concentration (cAb):** To determine suitable cAb concentration to spot, 1  $\mu\text{L}$   
11  
12 347 droplets containing 2 to 25  $\mu\text{g mL}^{-1}$  of cAb (0.002-0.025  $\mu\text{g}$  of cAb) were arrayed and the S/N of  
13  
14 348 ATPS ELISA performance determined as shown in Fig. 3(A). Signal increased as more cAb was  
15  
16 349 immobilized then leveled off. Because our plate preparation involves a step where excess cAb is  
17  
18 350 washed away prior to dAb spotting, higher cAb spotting does not lead to a hook effect where the  
19  
20 351 S/N decreases, in contrast to our previous method.<sup>24</sup> From these results, we selected cAb  
21  
22 352 concentration of 10  $\mu\text{g mL}^{-1}$  for IL-6, IL-10, TNF- $\alpha$ , IL-1 $\beta$  and CCL18.  
23  
24  
25  
26 353

27  
28 354 **Detection antibody (dAb):** Fig. 3(B) presents dAb concentration study to determine optimal dAb  
29  
30 355 concentrations for improving S/N. Specifically, concentration range of dAb from 1 to 75  $\text{ng mL}^{-1}$   
31  
32 356 (0.001-0.075  $\text{ng}$  of dAb) was tested. Curves reached a peak prior to reduction of S/N at higher  
33  
34 357 concentrations. The decrease in S/N at higher dAb concentration generally resulted from high  
35  
36 358 background signal. Based on these results we selected dAb concentration of 10  $\text{ng mL}^{-1}$  for IL-6,  
37  
38 359 25  $\text{ng mL}^{-1}$  for IL-10, TNF- $\alpha$ , IL-1 $\beta$  and CCL18.  
39  
40  
41  
42 360

43  
44 361 **HRP concentration:** HRP concentration plays important role to enhance S/N and it was tested as  
45  
46 362 shown in Fig. 3(C). The key takes away is that too little leads to weak signal while too much  
47  
48 363 leads to high background. The optimal amount of HRP in an assay also depends on the total  
49  
50 364 amount of biotinylated dAb that is present in an assay microwell because the streptavidin-  
51  
52 365 conjugated HRP is incubated together with the dAb before any excess is washed away, unlike  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 366 typical protocols. Based on these considerations, the optimum HRP concentration was found to  
4  
5 367 be 5× the manufacturer recommended concentration.  
6  
7

8 368

### 9 10 369 **3.2 Comparison of ELISA performance for multiplex detection**

11  
12 370 As an application for the newly developed one-incubation ATPS ELISA, we compare the ELISA  
13  
14 371 performance of three procedures (see Fig. 1(A-C) and Table 4) with the detection of a five-  
15  
16 372 cytokine panel (IL-6, IL-10, TNF- $\alpha$ , IL-1 $\beta$  and CCL18). These cytokines, produced by various  
17  
18 373 cell types including macrophages, are important modulators in immune responses and diseases  
19  
20 374 such as cancer, and autoimmune diseases.<sup>34</sup> Identifying the cytokine profile released in cell  
21  
22 375 culture supernatants aids in classifying cells into disease-relevant subsets, for example, M1 pro-  
23  
24 376 inflammatory versus M2 pro-regenerative macrophage populations.<sup>35</sup> Therefore, the five-  
25  
26 377 cytokine panel we developed tests typical markers for M1 (IL-6, TNF- $\alpha$ , IL-1 $\beta$ ) and M2 (IL-10,  
27  
28 378 CCL18) phenotypes. Calibration curves of one-incubation ATPS ELISA for analysis of  
29  
30 379 cytokines; (a) IL-6, (b) TNF- $\alpha$ , (c) IL-10, (d) IL-1 $\beta$  and (e) CCL18 are presented in (Fig. 4).  
31  
32 380 LOD, S/N and %CV for standard ELISA (No ATPS), two-incubation and one-incubation ATPS  
33  
34 381 ELISA are shown for each biomarker (Table 4).  
35  
36  
37  
38  
39

40 382

41  
42 383 LOD and S/N comparison between the three methods is shown in Fig. 1(A-C) for each cytokine  
43  
44 384 that was investigated. An improved LOD was observed for ATPS ELISA (*i.e.* one- and two-  
45  
46 385 incubation) compared to the standard ELISA, this may be because of decreased number of  
47  
48 386 washing steps. The intra-assay CV of one-incubation ATPS ELISA was <10% and not  
49  
50 387 significantly different from two-incubation ATPS ELISA (see Table 4). This work employed  
51  
52 388 black color plate for one-incubation ATPS ELISA for all multiplex detection, thus optical  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 389 crosstalk that lets the signal from bright microbasins and microwells spill into adjacent  
4  
5 390 microbasins and microwells was reduced.<sup>36</sup>  
6  
7

8 391  
9  
10 392 Table S1 summarizes previous reports of cytokines ELISA multiplex detection by employing  
11  
12 393 various techniques<sup>37</sup> (ESI 2). It is shown that our method provides short assay time (1 hour) and  
13  
14 394 high sensitivity (LOD = 1.8-7.6 pg mL<sup>-1</sup>) when compared to other methods.  
15  
16

17 395

### 19 396 **3.3 Measurement of human macrophage cytokine production**

21 397 We optimized the 5-plex detection assay to test the application of our one-incubation ELISA (see  
22  
23 398 Table 5 of summarized conditions for optimization studies). We measured the cytokine  
24  
25 399 production from ThP-1-derived human macrophages to compare the cytokine secretion of  
26  
27 400 differentially treated human macrophages (Fig. 5). In these treatments, the macrophages were  
28  
29 401 initially polarized towards an M1 or M2 phenotype for 48 hours, then the media exchanged and  
30  
31 402 late stage cytokine secretion in absence of any exogenous cytokines or LPS quantified.<sup>38, 39</sup> For  
32  
33 403 statistical analysis, a *t-test* analysis (unpaired *t-test*) between the differently treated macrophage  
34  
35 404 was performed; differences between groups were considered statistically significant when  $P <$   
36  
37 405 0.01. We detected higher IL-6 and IL-1 $\beta$ , characteristic of M1 polarization, when macrophages  
38  
39 406 were treated with LPS and IFN- $\gamma$ , while IL-10, characteristic of M2 polarization, was increased  
40  
41 407 in macrophage treated with IL-13 and IL-4 ( $P < 0.01$ ). Both sub-populations expressed TNF- $\alpha$   
42  
43 408 and CCL18 at similar levels ( $P > 0.05$ ) in this late stage (day 3 after polarization) secretion  
44  
45 409 analysis. Applying a one-incubation ELISA approach to test cytokine profiles of macrophage  
46  
47 410 supernatants generated results in one hour; faster than most commercially available options (5-  
48  
49 411 fold total assay time reduction compared to standard method). We did note a weakness and  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 412 caution required for the one-incubation assay, namely, interference by biotin. When the cell  
4  
5 413 culture media included a biotin additive, it inhibited the dAb-HRP interaction leading to reduced  
6  
7 414 signal. The results obtained in Fig. 5, thus used a media without biotin additive.  
8  
9

10 415

## 11 12 416 **4. Conclusion**

13  
14  
15 417

16  
17 418 We developed a one-incubation, one-hour multiplex immunoassay. We examined competing  
18  
19 419 factors that influence the selection of an ideal ATPS composition for rehydrated, multiplex  
20  
21 420 ELISA: namely antibody retention in the DEX phase, incubation time, choice of blocking buffer,  
22  
23 421 antibody concentration, and HRP concentration. We characterized the signal to noise ratio and  
24  
25 422 the limit of detection for our optimized ATPS ELISA and found improvements over our previous  
26  
27 423 work. Lastly, we demonstrated quantification of cytokines in macrophage supernatants that are  
28  
29 424 consistent with published literature. While this one-incubation assay is more convenient, we did  
30  
31 425 also note a weakness of eliminating the wash step before HRP incubation where biotin contained  
32  
33 426 in the sample solution could interfere with dAb-HRP interactions. Despite this caveat, from a  
34  
35 427 practical perspective, the one-incubation ATPS ELISA provides a convenient and high  
36  
37 428 sensitivity option for multiplex detection of cytokines. From the perspective of how to formulate  
38  
39 429 ATPSs for ELISA use, this work describes a conceptual shift from simply maximizing antibody  
40  
41 430 partitioning to optimizing the overall process that also includes mass transport and background  
42  
43 431 signal levels.  
44  
45  
46  
47  
48  
49

50 432

## 51 52 433 **Conflicts of interest**

53  
54  
55 434 There are no conflicts to declare.  
56  
57  
58  
59  
60

1  
2  
3 4354  
5  
6 436 **Acknowledgements**7  
8 4379  
10 438 We thank NIH (HL136141), NSF (CBET 0939511 & IIP1456281), and Science Achievement11  
12 439 Scholarship of Thailand (SAST) for financial support to M.T. M.M. was funded by the NIH-13  
14 440 sponsored Research Training Program in Immuno-engineering (T32EB021962). M.M. was15  
16 441 partially supported by the Alfred P. Sloan Foundation, G-2019-11435. Faculty of Graduate17  
18 442 Studies and Faculty of Science, Mahidol University, Center of Excellence for Innovation in19  
20 443 Chemistry (PERCH-CIC), Ministry of Higher Education, Science, Research and Innovation are21  
22 444 gratefully acknowledged.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

445 **References**

- 446 1. S. K. Vashist, E. Marion Schneider, E. Lam, S. Hrapovic and J. H. T. Luong, *Sci. Rep.*,  
447 2014, **4**, 4407.
- 448 2. J. Teng, L. Huang, L. Zhang, J. Li, H. Bai, Y. Li, S. Ding, Y. Zhang and W. Cheng, *Anal.*  
449 *Chim. Acta*, 2019, **1067**, 107-114.
- 450 3. S. M. I. Bari, L. G. Reis and G. G. Nestorova, *Biosens. Bioelectron.*, 2019, **126**, 82-87.
- 451 4. F. Zhou, M. Wang, L. Yuan, Z. Cheng, Z. Wu and H. Chen, *Analyst*, 2012, **137**, 1779-  
452 1784.
- 453 5. M.-S. Jeong and D.-R. Ahn, *Analyst*, 2015, **140**, 1995-2000.
- 454 6. X. Yu, D. Scott, E. Dikici, S. Joel, S. Deo and S. Daunert, *Analyst*, 2019, **144**, 3250-  
455 3259.
- 456 7. R. Tokarz, N. Mishra, T. Tagliafierro, S. Sameroff, A. Caciula, L. Chauhan, J. Patel, E.  
457 Sullivan, A. Gucwa, B. Fallon, M. Golightly, C. Molins, M. Schriefer, A. Marques, T.  
458 Briese and W. I. Lipkin, *Sci. Rep.*, 2018, **8**, 3158.
- 459 8. M. Pla-Roca, R. F. Leulmi, S. Tourekhanova, S. Bergeron, V. Laforte, E. Moreau, S. J.  
460 C. Gosline, N. Bertos, M. Hallett, M. Park and D. Juncker, *Mol. Cell. Proteomics*, 2012,  
461 **11**, M111.011460.
- 462 9. S. Fredriksson, M. Gullberg, J. Jarvius, C. Olsson, K. Pietras, S. M. Gústafsdóttir, A.  
463 Östman and U. Landegren, *Nat. Biotechnol.*, 2002, **20**, 473-477.
- 464 10. R. P. Ekins, *J. Pharm. Biomed. Anal.*, 1989, **7**, 155-168.
- 465 11. J. F. Djoba Siawaya, T. Roberts, C. Babb, G. Black, H. J. Golakai, K. Stanley, N. B.  
466 Bapela, E. Hoal, S. Parida, P. van Helden and G. Walzl, *PLoS One*, 2008, **3**, e2535.
- 467 12. M. A. Eddings, A. R. Miles, J. W. Eckman, J. Kim, R. L. Rich, B. K. Gale and D. G.  
468 Myszka, *Anal. Biochem.*, 2008, **382**, 55-59.
- 469 13. S. Natarajan, A. Hatch, D. G. Myszka and B. K. Gale, *Anal. Chem.*, 2008, **80**, 8561-8567.
- 470 14. F. a. Alshawawreh, F. Lisi, N. Ariotti, P. Bakthavathsalam, T. Benedetti, R. D. Tilley and  
471 J. J. Gooding, *Analyst*, 2019, **144**, 6225-6230.
- 472 15. S. Xu, W. Ouyang, P. Xie, Y. Lin, B. Qiu, Z. Lin, G. Chen and L. Guo, *Anal. Chem.*,  
473 2017, **89**, 1617-1623.
- 474 16. J. T. Kindt, M. S. Luchansky, A. J. Qavi, S.-H. Lee and R. C. Bailey, *Anal. Chem.*, 2013,  
475 **85**, 10653-10657.
- 476 17. G. Stybayeva, O. Mudanyali, S. Seo, J. Silangcruz, M. Macal, E. Ramanculov, S.  
477 Dandekar, A. Erlinger, A. Ozcan and A. Revzin, *Anal. Chem.*, 2010, **82**, 3736-3744.
- 478 18. Y.-C. Yang and W.-L. Tseng, *Anal. Chem.*, 2016, **88**, 5355-5362.
- 479 19. C. Liu, M. Skaldin, C. Wu, Y. Lu and A. V. Zavalov, *Sci. Rep.*, 2016, **6**, 31370.
- 480 20. S. X. Leng, J. E. McElhaney, J. D. Walston, D. Xie, N. S. Fedarko and G. A. Kuchel, *J.*  
481 *Gerontol., Ser. A*, 2008, **63**, 879-884.
- 482 21. J. A. Asenjo and B. A. Andrews, *J. Chromatogr. A*, 2011, **1218**, 8826-8835.
- 483 22. A. B. Simon, J. P. Frampton, N.-T. Huang, K. Kurabayashi, S. Paczesny and S.  
484 Takayama, *Technology* 2014, **2**, 176-184.
- 485 23. J. P. Frampton, J. B. White, A. B. Simon, M. Tsuei, S. Paczesny and S. Takayama, *Sci.*  
486 *Rep.*, 2014, **4**, 4878.
- 487 24. L. Eiden, C. Yamanishi, S. Takayama and J. F. Dishinger, *Anal. Chem.*, 2016, **88**, 11328-  
488 11334.



- 1  
2  
3 489 25. T. Xia, X. Xu, N. Zhao, Z. Luo and Y. Tang, *Clin. Microbiol. Infect.*, 2016, **22**, 996-  
4 490 1001.  
5 491 26. H. Kimura, M. Yoshizumi, H. Ishii, K. Oishi and A. Ryo, *Front. Microbiol.*, 2013, **4**,  
6 492 276.  
7 493 27. T. Kojima and S. Takayama, *Anal. Chem.*, 2013, **85**, 5213-5218.  
8 494 28. C. Yamanishi, C. R. Oliver, T. Kojima and S. Takayama, *Front. Chem.*, 2019, **7**, 311.  
9 495 29. K. L. Spiller, E. A. Wrona, S. Romero-Torres, I. Pallotta, P. L. Graney, C. E. Witherel, L.  
10 496 M. Panicker, R. A. Feldman, A. M. Urbanska, L. Santambrogio, G. Vunjak-Novakovic  
11 497 and D. O. Freytes, *Exp. Cell Res.*, 2016, **347**, 1-13.  
12 498 30. T. Yaguchi, M. Dwidar, C. K. Byun, B. Leung, S. Lee, Y.-K. Cho, R. J. Mitchell and S.  
13 499 Takayama, *Biomacromolecules*, 2012, **13**, 2655-2661.  
14 500 31. J. H. Crowe, F. A. Hoekstra and L. M. Crowe, *Annu. Rev. Physiol.*, 1992, **54**, 579-599.  
15 501 32. Z. Péterfi and B. Kocsis, *J. Immunoassay*, 2000, **21**, 341-354.  
16 502 33. K. Terato, C. T. Do, D. Cutler, T. Waritani and H. Shionoya, *J. Immunol. Methods*, 2014,  
17 503 **407**, 15-25.  
18 504 34. M. Genin, F. Clement, A. Fattaccioli, M. Raes and C. Michiels, *BMC Cancer*, 2015, **15**,  
19 505 577.  
20 506 35. R. Sridharan, A. R. Cameron, D. J. Kelly, C. J. Kearney and F. J. O'Brien, *Mater. Today*,  
21 507 2015, **18**, 313-325.  
22 508 36. O. Vallisuta and S. Olimat, *Drug Discovery and Development: From Molecules to*  
23 509 *Medicine*, BoD–Books on Demand, Norderstedt, Germany, 2015.  
24 510 37. G. Liu, M. Qi, M. R. Hutchinson, G. Yang and E. M. Goldys, *Biosens. Bioelectron.*,  
25 511 2016, **79**, 810-821.  
26 512 38. C. Bayer, S. Varani, L. Wang, P. Walther, S. Zhou, S. Straschewski, M. Bachem, C.  
27 513 Söderberg-Naucler, T. Mertens and G. Frascaroli, *J. Virol.*, 2013, **87**, 67-79.  
28 514 39. K. L. Spiller, S. Nassiri, C. E. Witherel, R. R. Anfang, J. Ng, K. R. Nakazawa, T. Yu and  
29 515 G. Vunjak-Novakovic, *Biomaterials*, 2015, **37**, 194-207.

35 516

36 517

## 518 List of Figure Captions

519  
520 **Fig. 1** Schematic of ELISA procedure: **(A)** Standard ELISA for singleplex detection, **(B)** Two-  
521 incubation ATPS ELISA and **(C)** One-incubation ATPS ELISA for multiplex detection.

522  
523 **Fig. 2** Effect of PEG-DEX concentration on FITC-dAb retention in DEX and ELISA reaction  
524 PEG-DEX concentration during the assay (%w/w); (a) 9%PEG-0.81%DEX, (b) 5%PEG-  
525 0.81%DEX, (c) 9%PEG-0.45%DEX, (d) 5%PEG-0.45%DEX, (e) 5%PEG-0.27%DEX, (f)  
526 3%PEG-0.45%DEX and (g) 3%PEG-0.27%DEX ; **(A)** Bar graph for percent of FITC-dAb  
527 retention in DEX droplets and S/N. This percent was measured by fraction of FITC-antibodies  
528 intensity in 1 hour and 0 minute multiplying with 100 from three replicate measurements, the  
529 error bars are standard deviations. S/N was performed from analysis of IL-6 with one-incubation  
530 ATPS ELISA. **(B)** Fluorescence images of FITC-dAb remaining in DEX droplets. **(C)** Blue  
531 points (●) in 35k PEG-500k DEX system represent overall concentration of PEG and DEX  
532 during the assay. The binodal curve (dotted curved line) determined by fitting line in R program.  
533 Measurements were conducted at 25 °C. **(D)** Calibration data for analysis of IL-6 with one-  
534 incubation ATPS ELISA in different PEG-DEX concentration (a-g) and the calculated LODs  
535 were 230, 25, 30, 1.8, 12, 95 and 270 pg mL<sup>-1</sup>, respectively. Data shown are mean  
536 chemiluminescence signals from three replicates, and error bars are standard deviations (SDs).

537  
538 **Fig. 3** Graphs for determination of optimal cAb, dAb and HRP concentrations. The error bars are  
539 standard deviations. Types of cytokine; (a) IL-6, (b) TNF- $\alpha$ , (c) IL-10, (d) IL-1 $\beta$  and (e) CCL18;

1  
2  
3 540 (A) cAb concentration (0-25  $\mu\text{g mL}^{-1}$ ), (B) dAb concentration (0-75  $\text{ng mL}^{-1}$ ) and (C) HRP  
4  
5 541 concentration ( $1\times$ - $15\times$ ).  
6  
7

8 542  
9

10 543 **Fig. 4** Calibration data for analysis of cytokines with one-incubation ATPS ELISA. Types of  
11  
12 544 cytokine; (a) IL-6, (b) TNF- $\alpha$ , (c) IL-10, (d) IL-1 $\beta$  and (e) CCL18 and the calculated LODs were  
13  
14 545 1.8, 2.4, 4.9, 7.6 and 3.7  $\text{pg mL}^{-1}$ , respectively. Data shown are mean chemiluminescence signals  
15  
16 546 from three replicates, and error bars are standard deviations (SDs).  
17  
18

19 547  
20

21  
22 548 **Fig. 5** Measurement of cytokine production by differentially-treated macrophage (LPS, IFN- $\gamma$   
23  
24 549 and IL-13, IL-4), n = 3 replicate measurements, error bars are SDs. “ns” indicates not significant  
25  
26 550 ( $p>0.05$ ), whereas \*\* indicates significant difference ( $p<0.01$ ) (unpaired *t-test*).  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

551 **List of Tables**






552 **Table 1** Previous ATPS ELISA method of cytokines detection (singleplex and multiplex), assay information included; assay time,  
 553 numbers of incubation, wash, material type, plate and microbasin properties, working range, S/N and LOD.

Cytokines detection	Assay time	Numbers (incubation, wash)	Material, type of plate, microbasin	Working range (pg mL <sup>-1</sup> )	S/N	LOD (pg mL <sup>-1</sup> )	Ref.
Singleplex* (Standard ELISA)	4 hours, 40 minutes	(Two, 9)	Polystyrene, clear plate, clear microbasin	3.91-2,000	IL-6 = 30.1 IL-10 = 15.0 TNF- $\alpha$ = 10.1 IL-1 $\beta$ = 30.1 IL-8 = 33.2	IL-6 = 9.4 IL-10 = 31.2 TNF- $\alpha$ = 15.6 IL-1 $\beta$ = 3.9 IL-8 = 7.8	Commercial R&D ELISA kit
Multiplex (AlphaLISA ATPS ELISA)	2 hours	(One, 0)	Polystyrene, black plate, white microbasin	1-1,200	N/A	IL-6 = 6.2 IL-8 = 20.6 CXCL9 = 20.1 CXCL10 = 11.8	Simon et al. 2014 <sup>22</sup>
Multiplex (ATPS ELISA)	5 hours	(Two, 18)	Polystyrene, clear plate, clear microbasin	1-10,000	N/A	HGF = 96 Elafin = 1,437 ST2 = 103 TNFR1 = 87	Frampton et al. 2014 <sup>23</sup>
Multiplex (ATPS ELISA)	4 hours, 20 minutes	(Two, 12)	Polystyrene, clear plate, clear microbasin	1-1,200	IL-6 = 30.2 IL-10 = 16.4 TNF- $\alpha$ = 7.6 IL-1 $\beta$ = 64.8 IL-8 = 19.3	IL-6 = <1.65 IL-10 = 3.40 TNF- $\alpha$ = 1.67 IL-1 $\beta$ = 2.05 IL-8 = 2.72	Eiden et. al 2016 <sup>24</sup>
Singleplex (ATPS ELISA)	15 minutes	(Two, 9)	Polystyrene, black plate, black microbasin	31.25-2,000	N/A	N/A	Yamanishi et. al 2019 <sup>28</sup>
Multiplex (ATPS ELISA)	1 hour	(One, 6)	Polystyrene, black plate, black microbasin	1-2,000	IL-6 = 30.3 IL-10 = 10.1 TNF- $\alpha$ = 27.2 IL-1 $\beta$ = 43.1 CCL18 = 43.5	IL-6 = 1.8 IL-10 = 4.9 TNF- $\alpha$ = 2.4 IL-1 $\beta$ = 7.6 CCL18 = 3.7	This work

554 \*Non ATPS: This assay is for method comparison











555 N/A: Not available

556 **Table 2** Effect of incubation time on ATPS ELISA (15 minutes, 1 hour and 4 hours). The  
 557 performance was carried out with information, LOD, CV (%) and S/N±SD (n=3) obtaining by  
 558 using each incubation time as listed below.

Incubation time	LOD (pg mL <sup>-1</sup> )	CV (%)	S/N±SD	ELISA image	
				Signal	Noise
15 minutes	180	9.1%	3.70±0.03		
1 hour	~1	1.4%	30.0±1.0		
4 hours	340	7.8%	1.6±0.1		

559

1  
2  
3 **Table 3** Images of dried spots employing different type of blocking buffer with 5% DEX  
4 containing IgG FITC-antibodies. A scale bar was 1000  $\mu\text{m}$ . Performing of ATPS ELISA was  
5 carried out with information, LOD, CV (%) and S/N $\pm$ SD (n=3) obtaining by using each blocking  
6  
7  
8  
9

Parameter	3 $\times$ StabilCoat	1 $\times$ StabilCoat	5%BSA	5%Goat serum	0.1%Chonblock/ 0.05%goat serum
Bright field images					
Fluorescence images					
Chemiluminescence value of the background $\pm$ SD (AU)	200,000 $\pm$ 5,000	300,000 $\pm$ 8,000	200,000 $\pm$ 100,000	400,000 $\pm$ 60,000	2,000,000 $\pm$ 200,000
LOD (pg mL <sup>-1</sup> )	$\sim$ 1	20	100	60	100
CV (%)	2	3	30	10	10
S/N $\pm$ SD	28.0 $\pm$ 0.6	26.0 $\pm$ 0.5	30.0 $\pm$ 15.0	10.0 $\pm$ 3.0	3.7 $\pm$ 0.3

564

566 **Table 4** Comparison of three ELISA methods (*i.e.* standard ELISA, two-incubation ATPS  
 567 ELISA and one-incubation ATPS ELISA). Comparison of LOD, CV (%) and S/N±SD (n=36)  
 568 in each method for detection of five cytokines.

Methods	IL-6	IL-10	TNF- $\alpha$	IL-1 $\beta$	CCL18
LOD (pg mL <sup>-1</sup> )					
Standard ELISA	9.4	31.2	15.6	3.9	7.8
Two-incubation ATPS ELISA	28.6	83.5	23.0	60.7	33.0
One-incubation ATPS ELISA	1.8	4.9	2.4	7.6	3.7
S/N					
Standard ELISA	30.1	15.0	10.1	30.1	33.2
Two-incubation ATPS ELISA	29.7	3.2	14.3	18.6	26.0
One-incubation ATPS ELISA	30.3	10.1	27.2	43.1	43.5
%CV					
Two-incubation ATPS ELISA	5.5%	4.7%	7.5%	9.8%	8.9%
One-incubation ATPS ELISA	6.6%	4.8%	6.4%	8.4%	8.8%

569

570 **Table 5** Summary of the investigated range and selected condition for one-incubation ATPS  
 571 ELISA.

Variable	Investigated range	Selected condition
1. PEG-DEX concentration	9%-0.81%, 5%-0.81%, 9%-0.45%, 5%-0.45%, 5%-0.27%, 3%-0.45% and 3%-0.27% (%w/w)	5%-0.45% (%w/w)
2. Incubation time	15 minutes, 1 hour and 4 hours	1 hour
3. Types of blocking buffer	3×StabilCoat, 1×StabilCoat, 5%BSA, 0.5%Goat serum and 0.1%Chonblock/0.05%goat serum	3×StabilCoat
4. cAb concentration	2, 4, 6, 8, 10, 15, 20 and 25 $\mu\text{g mL}^{-1}$	10 $\mu\text{g mL}^{-1}$
5. dAb concentration	1, 10, 25, 50 and 75 $\text{ng mL}^{-1}$	10 $\text{ng mL}^{-1}$ for IL-6, 25 $\text{ng mL}^{-1}$ for IL-10, TNF- $\alpha$ , IL-1 $\beta$ and CCL18
6. HRP concentration	1×, 3×, 5×, 10× and 15×	5×

572

573

574

575

576

577

578

579

580



## List of Figures




Fig. 1





Fig. 2





Fig. 2 (continued)




Fig. 3




Fig. 4





Fig. 5

# Graphical abstract



4 cm \* 8 cm

This work presents one-incubation one-hour multiplex ELISA enabled by aqueous two-phase systems for five-plex cytokine detection in human ThP-1 macrophages.